Real-life prognosis of neurological complications of botulinum toxin: A nationwide pharmacovigilance study of adverse drug reactions reported in France between 1994 and 2020.

Annals of physical and rehabilitation medicine 2025 Vol.68(3) p. 101924

Carpentier VT, Weiss N, Salem JE, Joussain C, Levy J, Mariani LL, Montastruc F, Mahé J, Lebrun-Vignes B, Bensmail D, Denys P, Genêt F, Bihan K

관련 도메인

Abstract

[BACKGROUND] Botulinum toxin is commonly used in the treatment of neurological disorders. Although neurological complications predominate and can lead to respiratory failure or death, no observational studies have specifically described their clinical features or prognoses.

[OBJECTIVES] To characterise real-life clinical features and prognoses of botulinum toxin-related neurological complications.

[METHODS] Observational, retrospective, nationwide pharmacovigilance study of all neurological adverse drug reactions (ADRs) related to the use of botulinum toxin in France for neurological indications between 1994 and 2020. The characteristics of neurological complications were collected.

[RESULTS] In total, 141 people with systemic neurologic complications (ie, distant from the injection site) and 50 with local complications were included. Median (IQR) age was 53 (36; 66) years, and 107 (56 %) were women. The estimated incidence range (min-max) was 25 - 413 neurologic ADRs per 100 000 injection sessions for neurological indications. Except for 3 miscellaneous cases, all presented symptoms within the clinical spectrum of botulism, either as an isolated symptom (41 %) or as multiple symptoms (59 %), with a time to onset of 12 (7; 15) days after injection and a duration of 54 (28; 90) days. A total of 87 % of cases recovered spontaneously or were recovering on the date of the notification. Drug types were not different between cases with systemic or local ADRs, although the doses were higher in cases with systemic ADRs (P < 0.001). Serious cases were more frequent for systemic ADRs (67 % versus 34 %; P < 0.001). Three complications resulted in death, all after treatment for cervical dystonia or sialorrhea.

[CONCLUSION] In this pharmacovigilance study, the outcomes of botulism spectrum symptoms occurring after a botulinum toxin injection for a neurological indication were mostly favourable, although symptoms were often initially serious.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 5
해부 cervical scispacy 1
약물 [BACKGROUND] Botulinum toxin scispacy 1
약물 [OBJECTIVES] scispacy 1
약물 [RESULTS] scispacy 1
질환 adverse drug reactions C0041755
Adverse reaction to drug
scispacy 1
질환 neurological disorders C0027765
nervous system disorder
scispacy 1
질환 neurological complications C0235029
neurological complication
scispacy 1
질환 respiratory failure C1145670
Respiratory Failure
scispacy 1
질환 death C0011065
Cessation of life
scispacy 1
질환 neurological adverse drug reactions scispacy 1
질환 systemic neurologic complications scispacy 1
질환 botulism C0006057
Botulism
scispacy 1
질환 dystonia C0013421
Dystonia
scispacy 1
질환 sialorrhea C0037036
Sialorrhea
scispacy 1
질환 botulism spectrum symptoms scispacy 1
기타 botulinum toxin: scispacy 1
기타 botulinum toxin-related scispacy 1
기타 people scispacy 1
기타 women scispacy 1

MeSH Terms

Humans; Pharmacovigilance; Female; France; Male; Middle Aged; Retrospective Studies; Adult; Aged; Nervous System Diseases; Botulinum Toxins; Prognosis; Neuromuscular Agents; Drug-Related Side Effects and Adverse Reactions; Botulism

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문